Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment
Rattachement africain : de, us, gb, at, ch, ua, Afrique du Sud, cn, gr, jp, it, ae. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Sex-based differences in morbidity and mortality in pulmonary hypertension (PH) are underexplored, yet understanding these differences is vital for improving clinical management. This study investigates the influence of sex on survival of patients with PH in dependency of various disease conditions. METHODS: The PVRI GoDeep meta-registry integrates data from international PH registries, of which we analysed 21,123 incident hemodynamically fully characterised patients with PH. Survival analyses employed Kaplan-Meier and Cox proportional hazards models, adjusted for confounders and subjected to sensitivity analyses. FINDINGS: Male patients consistently showed significantly higher mortality than females across the overall PH population (hazard ratio 1.36 [1.23, 1.50] after adjustment) and within PAH and non-PAH groups. These sex differences in survival persisted regardless of P(A)H severities, age and obesity, cardiovascular diseases, and PAH-specific therapies. The male survival disadvantage was noted across low-, intermediate-, and high-risk groups of the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores, but not the REVEAL 2.0 risk score, which incorporates male sex as non-modifiable factor. Stratification by race revealed that male sex was associated with worse survival in White patients, but not in Black or Asian patients with PH. INTERPRETATION: Male patients with PH exhibit significantly higher mortality risks than females across both PAH and non-PAH PH groups. This disparity persists regardless of PH severity, underlying cause, age, obesity, comorbidities, or treatment status, though race might modify the observed risk difference. These insights provide new avenues for investigating underlying mechanisms and suggest including male sex as an independent factor in clinical risk assessment tools. FUNDING: This work is funded by the Pulmonary Vascular Research Institute (PVRI) and the Cardiovascular Medical Research and Education Fund (CMREF), NIH.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment
- Date Crossref
- 01/01/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Universities of Giessen and Marburg Lung Center pays non établi dans la noticeUniversité ou école supérieure
-
Cardio-Pulmonary Institute pays non établi dans la noticeStructure de recherche
-
Vanderbilt University Medical Center pays non établi dans la noticeÉtablissement de santé
-
Royal Hallamshire Hospital pays non établi dans la noticeÉtablissement de santé
-
NIHR Sheffield Biomedical Research Centre pays non établi dans la noticeStructure de recherche
-
Imperial College London National Heart and Lung Institute pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Heidelberg University Center for Pulmonary Hypertension pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Heidelberg pays non établi dans la noticeÉtablissement de santé
-
German Center for Lung Research pays non établi dans la noticeStructure de recherche
-
Pulmonary and Allergy Associates pays non établi dans la noticeStructure de recherche
Universities of Giessen and Marburg Lung Center, Cardio-Pulmonary Institute et Vanderbilt University Medical Center, avec 9 autres affiliations. Pays d’affiliation : Afrique du Sud.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.